瑞波西汀对首发精神分裂症患者认知功能的影响(1)
 |
| 第1页 |
参见附件(3719KB，3页)。
【摘要】 目的 观察瑞波西汀对首发精神分裂症患者认知功能的影响。方法 采用随机、双盲对照法，将120例首发精神分裂症患者平均分为研究组(瑞波西汀+氟哌啶醇)和观察组(氟哌啶醇+安慰剂)。在治疗前，治疗后4、8、12周末分别以阳性症状和阴性症状量表(PNASS)和不良反应量表(TESS)评定疗效和不良反应，韦氏记忆量表(WMS)评定治疗前后患者认知功能的改变。结果 治疗12周后，研究组的韦氏记忆量表的再认、联想及记忆商(MQ)为：(9.5±2.3)、(10.8±1.7)、(103.7±12.9)；观察组分别为(8.4±1.5)、(9.1±1.6)、(90.5±11.9)，两组差异有统计学意义(P<0.05)。PANSS总分、阴性因子分及一般精神病理症状分比治疗前明显降低，治疗后4、8、12周末TESS评分，研究组均低于观察组，且治疗后低于治疗前，差异均有统计学意义(P<0.05)。结论 瑞波西汀对首发精神分裂症患者认知功能有明显改善，且不良反应减少。
【关键词】 精神分裂症；认知功能；瑞波西汀；氟哌啶醇
Effect ofReboxetine combined with Haloperidol in the treatment of first-episode schizophrenia on cognition function. SUN Jian, LIU Yong, WANG Hong-xia, et al. The Mental Hospital of Zhumadian,463000,China
【Abstract】 Objective To observe the cognition function of Reboxetine combined with Haloperidol in the treatment of schizophrenia.Methods Being used the vendom control stady,120 in-patients with chyonic schizophreaia were divided into study gooup (Reboxetine and Haloperidol) and control group(Haloperidol and comfort).Effects and side effects were assessed with PANSS and TESS respectively WMS were evaluated before treatment and after 4.8.12 weeks treatment.Results After treating 12 turnovers, The Wei surname of the research set memory quantity form of again recognize, association of thought and memory company(MQ) is:(9.5±2.3)、(10.8±1.7)、(103.7±12.9)；The matched control distinguishes for：(8.4±1.5)、(9.1±1.6)、(90.5±11.9)，two the sets show the difference of high(P<0.05).The todal scores of PANSS and the scores of negative factor were signficantly decreasedwith Reboxetine and Haloperidol.The TESS scores of study group were lower than that of coutrol group after 4.8.12weeks treatment,and the scores of post-treatment were lower than that of pre-treatment,so there were significant difference between those respectively.Conclusion It suggests that Reboxetine combined with Haloperidol,could improve distinctly the cognition function of schizophrenia patients and produce fewer side effects.
【Key words】 Schizophrenia;Cognition function;Reboxetine;Haloperidol
瑞波西汀(商品名：乐透康)是选择性去甲肾上腺素(NE)重摄取抑制剂,通过对NE再摄取的选择性阻滞，提高中枢内NE的活性，从而改善患者的情绪。临床用于治疗抑郁症。对5-羟色胺、多巴胺重吸收位点没有亲和力，对毒蕈碱、组胺或肾上腺素受体几无亲和作用。对抑郁症的治疗已有许多报道，尚未见瑞波西汀与典型抗精神病药氟哌啶醇联用对首发精神分裂症患者认知功能影响的对照研究报道，我们采用随机双盲法作此研究，现报告如下：
1 资料与方法
1.1 一般资料 为驻马店市精神病院2010年8月至2011年8月间住院或出院随访的首发精神分裂症患者 ......
您现在查看是摘要介绍页，详见PDF附件(3719KB，3页)。